Collegium Pharmaceutical (COLL) Change in Accured Expenses (2014 - 2026)

Collegium Pharmaceutical's Change in Accured Expenses history runs 13 years deep, the most recent figure standing at -$4.2 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 76.51% year-over-year to -$4.2 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 106.96% increase from a year earlier, with the FY2025 full-year figure at -$9.5 million, up 75.98% from the prior year.
• Change in Accured Expenses declined to -$4.2 million in Q1 2026 per COLL's latest filing, from $10.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $22.4 million in Q4 2024 and bottomed at -$62.9 million in Q3 2024.
• The 5-year median for Change in Accured Expenses is -$821000.0 (2022), against an average of -$3.7 million.
• Biggest YoY gain for Change in Accured Expenses was 1635.09% in 2025; the steepest drop was 2777.73% in 2025.
• Year by year, Change in Accured Expenses stood at $13.6 million in 2022, then slumped by 62.42% to $5.1 million in 2023, then jumped by 339.04% to $22.4 million in 2024, then slumped by 52.26% to $10.7 million in 2025, then plunged by 138.79% to -$4.2 million in 2026.
• Per Business Quant, the three latest COLL Change in Accured Expenses figures stand at -$4.2 million (Q1 2026), $10.7 million (Q4 2025), and -$8.1 million (Q3 2025).